Providing Uncommon Expertise For Your Oncology Program

Our award-winning, specialized early phase oncology team helps emerging and established biopharma, biotech, and pharmaceutical companies accelerate the advancement of early phase compounds through clinical testing.

The competitive landscape for oncology research is at an all-time high, and trial designs are increasing in complexity. Recent reports indicate that the success rate of investigational compounds approved for clinical use in cancer is the lowest among all diseases, and the likelihood of approval for investigational oncology drugs tested in Phase I trials is only 6.7 percent.1 Who you select as your CRO partner can have a significant impact on the success and/or failure of your clinical study and program. Who can you trust to help you with your development journey?